EMEA-001501-PIP04-19

Table of contents

Key facts

Invented name
Dupixent
Active substance
dupilumab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0059/2020
PIP number
EMEA-001501-PIP04-19
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of eosinophilic esophagitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Regeneron Ireland DAC

Tel. +1 9148 475385
E-mail: clinicaltrials@regeneron.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating